The ORR was 32% (35% in TNBC and 30% in HR+/HER2−).97 Another study, the VALENTINE trial (NCT05569811), is testing chemotherapy or patritumab deruxtecan in early HR-positive, HER2-negative, and high-risk breast cancer. Here, ERBB2 is linked to breast carcinoma.